

3-13

Secretary of State
Certificate and Order for Filing
PERMANENT ADMINISTRATIVE RULES

I certify that the attached copies* are true, full and correct copies of the PERMANENT Rule(s) adopted on February 15, 2007 by the
Date prior to or same as filing date

Oregon State Board of Nursing
Agency and Division

851
Administrative Rules Chapter Number

KC Cotton

800 N.E. Oregon Street, Suite 465
Portland, Oregon 97232

(971) 673-0638

Rules Coordinator

Address

Telephone

to become effective upon filing. Rulemaking Notice was published in the January 2007 Oregon Bulletin.**
Date upon filing or later Month and Year

RULE CAPTION

Advanced Practice Formulary Updated.

Not more than 15 words that reasonably identifies the subject matter of the agency's intended action.

RULEMAKING ACTION

List each rule number separately (000-000-0000)

Secure approval of new rule numbers (Adopted or Renumbered rules) with the Administrative Rules Unit prior to filing.

ADOPT:

AMEND: OAR 851-056-0012

REPEAL:


RENUMBER:

AMEND & RENUMBER:

Stat. Auth.: ORS 678.385, 678.390

Other Auth.:

Stats. Implemented: ORS 678.370, 678.372, 678.375, 678.380, 678.385, 678.390



RULE SUMMARY

The Board is authorized by ORS 678.385 and 678.390 to determine by rule and revise periodically the drugs and medicines to be included in the formulary that may be prescribed by a nurse practitioner or clinical nurse specialist under ORS 678.375, including controlled substances listed in Schedules II, III, III N, IV and V. This amendment adds the November and December 2006, and January 2007 updates to Drug Facts and Comparisons to the formulary, with specific drugs proposed for inclusion or deletion.

Authorized Signer

Joan Bouchard

Printed name

3/9/07

Date

*With this original, file one photocopy of certificate, one paper copy of rules listed in Rulemaking Actions, and electronic copy of rules. **The Oregon Bulletin is published the 1st of each month and updates rules found in the OAR Compilation. For publication in Bulletin, rule and notice filings must be submitted by 5:00 pm on the 15th day of the preceding month unless this deadline falls on a weekend or legal holiday, when filings are accepted until 5:00 pm on the preceding workday.

ARC 930-2005

BN 2-2007

Formulary for Clinical Nurse Specialists and Nurse Practitioners with Prescriptive Authority
851-056-0012

- (1) The following definitions apply for the purpose of these rules:
 - (a) "Appliance or device" means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component part or accessory which is required under federal or state law to be prescribed by a practitioner and dispensed by a pharmacist.
 - (b) "Formulary" means a specific list of drugs determined by the Board. The formulary for nurses with prescriptive authority shall be all the drugs in the Drug Facts and Comparisons dated January 2007, with the exception of certain drugs and drug groups which are listed below.
 - (c) "Board" means the Oregon State Board of Nursing.
- (2) The Board as authorized by ORS 678.385 shall determine the drugs which clinical nurse specialists and nurse practitioners with prescriptive authority may prescribe, shall periodically revise the formulary by rulemaking hearing at each regular Board meeting, and shall transmit the list of those drugs which are exceptions to the formulary, and which may not be prescribed to nurses with prescriptive authority and other interested parties.
- (3) The formulary is constructed based on the following premises:
 - (a) Nurse practitioners may provide care for specialized client populations within each nurse practitioner category/scope of practice;
 - (b) Clinical nurse specialists may provide care for individuals and populations within their specialty scope of practice;
 - (c) Prescribing is limited by the individual's scope of practice and knowledge base within that scope of practice;
 - (d) Clinical nurse specialists and nurse practitioners may prescribe the drugs appropriate for patients within their scope of practice as defined by OAR 851-050-0005; or OAR 851-054-0020 and 0021;
 - (e) Clinical nurse specialists and nurse practitioners shall be held strictly accountable for their prescribing decisions;
 - (f) All drugs on the formulary shall have Food and Drug Administration (FDA) approval.
- (4) Clinical nurse specialists and nurse practitioners with prescriptive authority are authorized to prescribe:
 - (a) All over-the-counter drugs;
 - (b) Appliances and devices.
- (5) Clinical nurse specialists and nurse practitioners are authorized to prescribe the following drugs as listed in Drug Facts and Comparisons dated January 2007:
 - (a) Nutrients and Nutritional Agents - all drugs except Flavocoxid (Limbrel);
 - (b) Hematological Agents - all drugs except Drotrecogin Alfa (Xigris); and Treprostinil Sodium (Romodulin).
 - (c) Endocrine and Metabolic Agents - all drugs except:
 - (A) I 131;

- (B) Gallium Nitrate; and
- (C) Mifepristone (Mifeprex); and
- (D) Abarelix (Plenaxis).
- (d) Cardiovasculars - all drugs except:
 - (A) Cardioplegic Solution;
 - (B) Fenoldopam Mesylate (Corlopam);
 - (C) Dofetilide (Tikosyn); and
 - (D) Bosentan (Tracleer).
- (e) Renal and Genitourinary Agents - all drugs;
- (f) Respiratory Agents - all drugs;
- (g) Central Nervous System Agents- all drugs with the following provisions:
 - (A) Class II Controlled Substances - Only the following drugs:
 - (i) Tincture of opium;
 - (ii) Codeine;
 - (iii) Hydromorphone;
 - (iv) Morphine;
 - (v) Oxycodone, Oxymorphone;
 - (vi) Topical Cocaine Extracts and Compounds;
 - (vii) Fentanyl;
 - (viii) Meperidine;
 - (ix) Amphetamines;
 - (x) Methylphenidates;
 - (xi) Pentobarbital;
 - (xii) Secobarbital;
 - (xiii) Methadone Hydrochloride (in accordance with OAR 851-045-0015(2)(n) and OAR 851-056-0026; and
 - (xiv) Levorphanol.
- (B) General Anesthetic Agents - no drugs which are general anesthetic barbiturates, volatile liquids or gases, with the exception of nitrous oxide.
- (C) Chymopapain is excluded.
- (D) Ziconotide (Prialt) is excluded.
- (h) Gastrointestinal Agents - all drugs except: Monooctanoin;
- (i) Anti-infectives, Systemic - all drugs;
- (j) Biological and Immunologic Agents - all drugs except Basiliximab (Simulect);
- (k) Dermatological Agents - all drugs except Psoralens;
- (l) Ophthalmic and Otic Agents - all drugs except:
 - (A) Punctal plugs;
 - (B) Collagen Implants;
 - (C) Indocyanine Green;
 - (D) Hydroxypropal (Methyl) Cellulose;
 - (E) Polydimethylsiloxane;
 - (F) Fomivirsen Sodium (Vitravene);
 - (G) Verteporfin;
 - (H) Levobetaxolol HCL (Betaxon);
 - (I) Travoprost (Travatan);

- (J) Bimatoprost (Lumigan);
- (K) Unoprostone Isopropyl (Rescula);
- (L) Pegaptanib Sodium (Macugen);
- (M) Triptan Blue (VisionBlue);
- (N) Retisert; and
- (O) Ranibizumab (Lucentis).
- (m) Antineoplastic Agents - all drugs except:
 - (A) NCI Investigational Agents;
 - (B) Samarium Sm53;
 - (C) Denileukin Diftitox (Ontak);
 - (D) BCG, Intravesical (Pacis);
 - (E) Arsenic Trioxide (Trisenox);
 - (F) Ibritumomab Tiuxetan (Zevalin);
 - (G) Tositumomab and Iodine 131 I-Tositumomab (Bexxar);
 - (H) Sclerosol; and
 - (I) Clofarabine (Clolar).
- (n) Diagnostic Aids:
 - (A) All drugs except Arbutamine (GenESA);
 - (B) Thyrotropin Alfa (Thyrogen);
 - (C) Miscellaneous Radiopaque agents - no drugs from this category except:
 - (i) Iopamidol;
 - (ii) Iohexol; and
 - (iii) Ioxilan (Oxilan).

Stat. Auth.: ORS 678.385

Stats. Implemented: ORS 678.385, 678.390